Scarica l'app Stockscreener
75.69
1.25%
-0.96
Pre-mercato:
75.50
-0.19
-0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$76.65
Aprire:
$76.6
Volume 24 ore:
3.13M
Relative Volume:
0.55
Capitalizzazione di mercato:
$29.21B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
32.37
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
-0.86%
1M Prestazione:
+4.44%
6M Prestazione:
+7.01%
1 anno Prestazione:
-9.77%
Intervallo 1D:
$75.66
$77.08
Intervallo di 1 settimana:
$72.08
$79.15
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
75.69 | 29.21B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
101.66 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
319.14 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.29 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.77 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.00 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Form 4 DexCom Inc For: 16 July By Investing.com - Investing.com Nigeria
Dexcom stock trades steady as CGM demand supports revenue growth - ad-hoc-news.de
Truist raises DexCom stock price target to $87 on growth outlook By Investing.com - Investing.com South Africa
Dexcom EVP chief legal compliance off sells $126,514 in stock By Investing.com - Investing.com South Africa
DEXCOM INC : TRUIST SECURITIES RAISES TARGET PRICE TO $87 FROM $80 - Bitget
ETFs Investing in DexCom, Inc. Stocks - TradingView
DexCom Inc (DXCM) Stock Up 7.2% and Still Undervalued -- GF Scor - GuruFocus
DexCom, Inc.’s stock price soars to $77.98, marking a remarkable 7.22% increase - Smartkarma
Dexcom EVP chief legal compliance off sells $126,514 in stock - Investing.com
DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4 - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why DexCom (DXCM) Stock Is Up Today - Quiver Quantitative
Why DexCom Inc (DXCM) Is Set to Outperform the Market: Insights into Financial Growth and Competitive Advantage - GuruFocus
Truist raises DexCom stock price target to $87 on growth outlook - Investing.com
Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating - marketscreener.com
US252131AM9 Bond Profile — Key Metrics - TradingView
How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story - simplywall.st
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DXCM Company (NASDAQ: DXCM) shareholder to sell 1,700 shares - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM - Zacks Investment Research
Dexcom G7 15 Day CGM System Receives Health Canada Approval - Medical Product Outsourcing
Dexcom receives Health Canada authorization for G7 15 Day CGM By Investing.com - Investing.com South Africa
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights - GlobeNewswire Inc.
Dexcom (DXCM) Gains Health Canada Approval for New CGM System - GuruFocus
Dexcom G7 15 Day Receives Health Canada Authorization: Extending - GuruFocus
Dexcom receives Health Canada authorization for G7 15 Day CGM - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DEXCOM,-INC. - The Facts
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes - Dexcom Investor Relations
Here's why you should retain DexCom stock in your portfolio - MSN
Dexcom stock holds steady on its glucose monitor business - Ad Hoc News
JPMorgan (NYSE: JPM) sells $2.01M DexCom-linked auto callable contingent interest notes - Stock Titan
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom to release Q2 2026 earnings on July 30, 2026 - scanx.trade
Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems? - Sahm
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured - Yahoo Finance
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):